RE:RE:RE:Well this announcement has me confused?They were running a Placebo controlled study for Metabolic Syndrome and Type II Diabetes, but from what I understand that has been post-poned and it seems they may target this indication wth amother analogue of 4050.
More transparency would be nice. We have been hearing about the CKD study for years and now it looks like that may be post poned as well.
Kinda sad that they are JUST NOW trying to minimize spending... why announce cystic fibrosis, scheloderma, CKD, Fibrinogen, C1, etc... and now plans have changed... shows how scattered Pierre is and I think this is the Board finally starting to control him.
Another main reason for the alignment? How do you partner 4050 if you are targeting 5 indications? The partner will want them all, not just a single indication. There is also the issue of pricing for various indications on the samw drug.
So now they will try to have 1 or 2 indications tops for 4050 and each analogue making it easier to partner, but further delays as new analogues will start in phase I.
The good news? IPF, Alstrom, Plasminogen, and IVIG alone is all we need at this point - if we deliver on those fronts we can command a big SP rise over the next couple years.